Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients

References

• NICE publishes final draft guidance on telaprevir for chronic hepatitis C. London, UK: NICE, 2012. http://www.nice.org.uk/newsroom/pressreleases/FinalDraftTelaprevirHepC.jsp. Accessed 2012
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• FDA. FDA approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). USA: FDA, 2011. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm. Accessed 2011
   Google Scholar
• FDA. FDA approval of Victrelis (boceprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). USA: FDA, 2011. URL:http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm. Accessed 2011
   Google Scholar
• EMA. EMA approval for Incivo (telaprevir): EMEA/H/C/002313. EMA, 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002313/human_med_001487.jsp&mid=WC0b01ac058001d124. Accessed 2011
   Google Scholar
• EMA. EMA approval for Victrelis (boceprevir): EMEA/H/C/002332. EMA, 2011.
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
   Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205, iii
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-210
   PubMed Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
   PubMed Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-5
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Vierling J, Flamm S, Gordon S, et al. Efficacy of Boceprevir in prior null responders to peginterferon/ribarivin: the PROVIDE study. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; San Francisco, CA. November 4--8, 2011
   Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Clinical study report: ADVANCE. 2010.
   Google Scholar
• Curtis L. Unit costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, University of Kent, 2010
   Google Scholar
• Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain 9 A.D.No.58, 2011
   Google Scholar
• Prescription drug database and drug prescribing guide. MIMS online. 2012
   Google Scholar
• Cure S, Diels J, Gavart S, et al. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin 2012;28:1841-56
   Google Scholar
• Flamm S, Lawitz E, Jacobson I, et al. High sustained virologic responses among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus peginterferon Alfa-2a/Ribavirin. European Association for the Study of the Liver, 2011
   Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisals. 2008. London, UK: NICE. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 2011
   Google Scholar
• Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010;40:950-9
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Health technology appraisal - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part-review of TA75 and TA106). London, UK: NICE, 2009
   Google Scholar
• Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent variants in telaprevir phase 3 clinical trials. Europen Association for the Study of the Liver, 2011
   Google Scholar
• Levin J. Telaprevir resistance disappears in 89% of patients: Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis from the EXTEND study. Boston, MA: American Association for the Study of Liver Diseases, 2010
   Google Scholar